COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Acute Phase Proteins as Early Markers in Sepsis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00641355
Recruitment Status : Unknown
Verified March 2008 by University of Zurich.
Recruitment status was:  Not yet recruiting
First Posted : March 24, 2008
Last Update Posted : March 24, 2008
Information provided by:
University of Zurich

Brief Summary:

Monitoring of different serumproteins after severe trauma and during trauma-induced sepsis.

  • Trial with surgical intervention

Condition or disease Intervention/treatment
Sepsis Procedure: No intervention

Layout table for study information
Study Type : Observational
Estimated Enrollment : 15 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Acute Phase Proteins as Early Markers in Sepsis
Study Start Date : April 2008
Estimated Study Completion Date : September 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Sepsis

Intervention Details:
  • Procedure: No intervention
    No intervention

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with severe trauma

Inclusion criteria:

  • Patients with severe trauma (ISS score > 16), both genders, patients on ICU

Exclusion criteria:

  • Moribund patients (pH <7,1, lactate >15mmol, Basedeficit > 15mEq/L, severe heart or liver injuries, GCS never over 5 after trauma)
  • Severe head injuries (AIS head >4)
  • Patient with severe infectious diseases, or diseases which severely affect the immune system (diabetes, Alkohol or nicotine abuse)
  • Non-german speaking patients

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00641355

Layout table for location contacts
Contact: 01 Studienregister MasterAdmins +41 (0)44 255 11 11

Layout table for location information
Zurich, Switzerland
Sponsors and Collaborators
University of Zurich
Layout table for investigator information
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
Layout table for additonal information
Responsible Party: PD Dr. Marius Keel, University Hospital of Zurich Identifier: NCT00641355    
Other Study ID Numbers: StV 26-2007
First Posted: March 24, 2008    Key Record Dates
Last Update Posted: March 24, 2008
Last Verified: March 2008
Additional relevant MeSH terms:
Layout table for MeSH terms
Systemic Inflammatory Response Syndrome
Pathologic Processes